SCHEMBL3011622

SCHEMBL3011622

O=S(=O)(c1cccc(Cl)c1)C1CCN(c2nc(Cc3cc(F)cc(F)c3)cs2)CC1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
GPR6 P46095 1/20 0.35
HTR2A P28223 5/20 0.35
CTSS P25774 1/20 0.35
DRD2 P14416 3/20 0.34
HTR2C P28335 3/20 0.34
KCNH2 Q12809 3/20 0.34
GRM5 P41594 2/20 0.34
MAPT P10636 2/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.34
NPC1 O15118 1/20 0.34
RIPK1 Q13546 1/20 0.34
EPHX2 P34913 1/20 0.34
CTPS1 P17812 1/20 0.34
HTR6 P50406 2/20 0.34
HTR7 P34969 1/20 0.34
POLB P06746 1/20 0.33
KCNA5 P22460 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3015977 0.96 RAB9A (0.38) RAB9ASMN1; SMN2GPR6HTR2ACTSS
SCHEMBL3013306 0.92 RAB9A (0.42) RAB9ASMN1; SMN2HTR2AHTR2CKCNH2
SCHEMBL2998070 0.92 GPR6 (0.42) RAB9ASMN1; SMN2GPR6HTR2ACTSS
SCHEMBL3022816 0.91 HTR2A (0.35) RAB9ASMN1; SMN2HTR2ACTSSDRD2
SCHEMBL2999678 0.91 GPR6 (0.39) RAB9ASMN1; SMN2GPR6HTR2ACTSS
SCHEMBL3013066 0.90 RAB9A (0.39) RAB9ASMN1; SMN2GPR6HTR2ACTSS
SCHEMBL3011199 0.90 GPR6 (0.41) RAB9ASMN1; SMN2GPR6HTR2ACTSS
SCHEMBL3013512 0.90 HTR2A (0.44) RAB9ASMN1; SMN2HTR2AHTR2CKCNH2
SCHEMBL3003047 0.90 RAB9A (0.41) RAB9ASMN1; SMN2HTR2ADRD2HTR2C
SCHEMBL3015772 0.90 HTR2A (0.44) RAB9ASMN1; SMN2GPR6HTR2ADRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA RAB9A 2943/4885SMN1; SMN2 1/4885GPR6 4245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.